生命科学产业十大策略要务（2025 年）

生命科学产业的不断发展和挑战要求相关人员保持适应性、创新和竞争力才能取得成功。产业领导者必须每年重新思考他们的策略地位，了解转型背后的关键力量：潜力、挑战和驱动力。

本报告研究了全球生命科学产业，并提供了市场概况、策略要务和成长机会。

目录

策略要务

• 成长为何变得越来越艰难？
• 策略要务
• 影响生命科学发展的关键变革
• 主要行业趋势和挑战

到 2025 年影响生命科学发展的十大变革

• 转型 1：SaaS 的进步将为实验室提供自适应智能
• 转型二：CDMO 加强新模式能力，数位转型实现端到端伙伴关係
• 转型三：将直接面向消费者 (DTC) 的基因检测从血统检测扩展到多致病性行为感染传染病
• 转型四：贸易战的不确定性扰乱医药供应链
• 转型五：透过分散临床试验（DCT）和罕见疾病提高CGT效率
• 第六次革命：次世代定序（NGS）和液态生物检体将彻底改变肿瘤诊断
• 变化七：临床试验失败和市场条件变化阻碍了生物技术创新
• 转型 8：ESG倡议成为 CEO 策略重点
• 转型 9：现实世界洞察 (RWI) 成为重新思考商业策略的策略指南
• 革命#10：CRISPR 技术推动生技药品研发
• 分析观点

后续步骤Next steps

Key Challenges, Trends, and Changes Transforming the Life Sciences Industry

Owing to constant developments and challenges in the life sciences industry, stakeholders must continue to be adaptable, innovative, and competitive to thrive. Industry leaders must reconsider their strategic positions annually by understanding the main forces behind the transformation, including potential, challenges, and drivers.

This analysis explores the strategic imperatives shaping and transforming the life sciences industry. They are as follows: SaaS evolution provides adaptive intelligence for laboratories CDMOs augment competencies in new modalities, and digital transformation delivers end-to-end partnerships Expanding direct-to-consumer (DTC) genetic testing beyond ancestry testing to multi-pathogenic STIs Uncertainty about trade wars disrupts pharmaceutical supply chains Decentralized clinical trials (DCTs) boost efficiency for CGTs and rare disorders Next-generation sequencing (NGS) and liquid biopsy revolutionize oncology diagnostics Failed clinical trials and shifting market conditions setback biotech innovation ESG initiatives climb to the top of CEOs' strategic priorities Real-world insight (RWI) emerges as a strategic compass point to reimagine commercial strategies CRISPR technology advances biologics R&D

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• Top Transformations Impacting the Growth of the Life Sciences Industry
• Key Industry Trends and Challenges

Top 10 Transformations Impacting Growth in the Life Sciences Industry, 2025

• Transformation 1: SaaS Evolution Provides Adaptive Intelligence for Laboratories
• Transformation 2: CDMOs Augment Competencies in New Modalities, and Digital Transformation Delivers End-to-End Partnerships
• Transformation 3: Expanding Direct-to-Consumer (DTC) Genetic Testing Beyond Ancestry Testing to Multi-pathogenic STIs
• Transformation 4: Uncertainty About Trade Wars Disrupts Pharmaceutical Supply Chains
• Transformation 5: Decentralized Clinical Trials (DCTs) Boosting Efficiency for CGTs and Rare Disorders
• Transformation 6: Next-generation Sequencing (NGS) and Liquid Biopsy Revolutionize Oncology Diagnostics
• Transformation 7: Failed Clinical Trials and Shifting Market Conditions Setback Biotech Innovation
• Transformation 8: ESG Initiatives Climb to the Top of CEOs' Strategic Priorities
• Transformation 9: Real-world Insight (RWI) Emerges as a Strategic Compass Point to Reimagine Commercial Strategies
• Transformation 10: CRISPR Technology Advances Biologics R&D
• Frost & Sullivan Analytics Perspectives

Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• Legal Disclaimer